Sorry, but I don'y buy your argument. I doubt that the number of people that will be getting 2-73 under the SAS is going to make even the smallest dent in the AD care costs.
Placebo controlled trials are still the standard. That maybe changing but as of now they are the standard with the possible exception of some cancer trials. I did a look recently at the cancer trials and most of them are still controlled trials. The control may not be a placebo, it may be the current SOC.
Of course there is no real SOC for most of the diseases that 2-73 is being tested on, so placebo it is.
News 
Market Data 
Discover 
AI
